Top Markets
#1 Islamic Coin Islamic Coin +158.15%
#2 Glidr Glidr +58.56%
#3 Cryptopia Cryptopia +19.80%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#5 Victoria VR Victoria VR +8.64%
#6 DMT-NAT DMT-NAT +6.65%
#7 Pons Pons +6.24%
#8 COTI COTI +6.21%
#9 龙虾 (Lobster) 龙虾 (Lobster) +5.86%
#10 Movement Movement +5.43%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rang in aandelen #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Aandeelprijs
$0.0005
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$10.28K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Categorie

Healthcare
Prijs VIAP met de marktkapitalisatie van B
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
VIAP
$0.0005
Marktkapitalisatie van VIA Pharmaceuticals, Inc.(VIAP)
Marktkapitalisatie: $10.28K
Vanaf August 2026 heeft VIA Pharmaceuticals, Inc. een marktkapitalisatie van $10.28K. Dit maakt VIA Pharmaceuticals, Inc. volgens onze gegevens het 41780th meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van VIA Pharmaceuticals, Inc. van 2007 tot 2026
VIAP vergeleken met de top 5 populairste stocks
Prijs voor VIAP Aandeel B Marktkapitalisatie van B uitslagen
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$261,862 $10.28K
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.383T +52,372,404,414.06%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$215,166 $10.28K
Apple Inc. Apple Inc.
AAPL
$4.423T +43,033,283,329.69%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$202,372 $10.28K
Alphabet Inc. Alphabet Inc.
GOOG
$4.160T +40,474,456,550.28%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$178,194 $10.28K
Microsoft Corporation Microsoft Corporation
MSFT
$3.663T +35,638,883,419.80%
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.
$140,638 $10.28K
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.891T +28,127,529,770.61%